NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs

Share :
Published: 27 Sep 2015
Views: 3772
Prof Philippe Ruszniewski - Paris Diderot University, Paris, France

Prof Ruszniewski presents the results from a multi-centre randomised international trial of 177Lu-DOTATATE, at a press conference at ECC 2015.

Results of this international, multicentre, randomised, open-label trial showed that the radiolabeled somatostatin analogue 177Lutetium-DOTATATE produced a significant improvement in progression-free survival when compared to octreotide LAR in patients with mid-gut neuroendocrine tumours.

Watch the interview or read the news story for more.